Medicare IVIG Access Enhancement Act of 2023
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Medicare IVIG Access Enhancement Act of 2023 is a legislative proposal introduced in the House during the 118th Congress aimed at improving access to intravenous immunoglobulin (IVIG) treatments for Medicare beneficiaries. The bill was referred to the Subcommittee on Health but did not advance further and ultimately failed or expired. No official summary or full text is available, limiting detailed analysis of its provisions.
This bill sought to enhance Medicare beneficiaries' access to IVIG treatments but did not progress beyond initial committee referral and expired without enactment.
- Introduced in the House during the 118th Congress as H.R. 5818.
- Focused on improving access to intravenous immunoglobulin (IVIG) therapies under Medicare.
- Referred to the Subcommittee on Health on December 17, 2024, but did not advance and expired.
['Medicare beneficiaries requiring IVIG treatments', 'Healthcare providers administering IVIG', 'Pharmaceutical companies producing IVIG products']
['Lack of available full bill text limits understanding of specific implementation mechanisms and funding sources.', 'No information on oversight or enforcement provisions to ensure effective access enhancement.', 'Unclear cost implications for Medicare and potential budgetary impact.']
The bill was introduced in the House and referred to the Subcommittee on Health during the 118th Congress but did not advance further. The absence of official summary and full text suggests limited legislative activity or support, resulting in the bill's failure or expiration.
Hidden impact flags detected: 1
GovScope reviewed 1 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential increased demand for IVIG treatments among Medicare beneficiaries if access were improved.', 'Possible budgetary pressures on Medicare due to expanded coverage or utilization of IVIG therapies.', 'Healthcare providers may need to adjust service delivery to accommodate changes in IVIG access.']
The absence of a full bill text and official summary hinders transparency and public understanding of the bill's specific provisions and potential impacts. This limits effective oversight and informed discussion by stakeholders and the public.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.